HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2( ) Tumors

Mikolaj Medon; Eva Vidacs; Stephin J Vervoort; Jason Li; Misty R Jenkins; Kelly M Ramsbottom; Joseph A Trapani; Mark J Smyth; Phillip K Darcy; Peter W Atadja; Michael A Henderson; Ricky W Johnstone; Nicole M Haynes

Journal article

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2( ) Tumors

Mikolaj Medon, Eva Vidacs, Stephin J Vervoort, Jason Li, Misty R Jenkins, Kelly M Ramsbottom, Joseph A Trapani, Mark J Smyth, Phillip K Darcy, Peter W Atadja, Michael A Henderson, Ricky W Johnstone, Nicole M Haynes

Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2017

DOI: 10.1158/0008-5472.CAN-16-2247

University of Melbourne Researchers

Phillip Darcy Author The Sir Peter MacCallum Department of Oncology

Michael Henderson Author Surgery - St Vincent's Hospital

Nicole Haynes Author The Sir Peter MacCallum Department of Oncology

Ricky Johnstone Author The Sir Peter MacCallum Department of Oncology

Jason Li Author The Sir Peter MacCallum Department of Oncology

Grants

Funding Acknowledgements

This work was financially supported by Victorian Breast Cancer Research Consortium (R.W. Johnstone, M. Medon, and N. M. Haynes); National Health and Medical Research Council of Australia (NHMRC) and Victorian Cancer Agency (R.W Johnstone); Cancer Council of Victoria (N. M. Haynes and R.W. Johnstone).